Pasithea Therapeutics (KTTA) Price Target: AI vs Analyst Consensus
Our AI model gives Pasithea Therapeutics (KTTA) a 6-month price target of $0.59, representing 1.7% potential upside from the current price of $0.58. The forecast combines financial fundamentals, technical analysis, and 25+ alternative data signals, including hiring trends, web traffic, employee sentiment, and social media activity. Pasithea Therapeutics’s current AI Score is 53/100 (Neutral).
KTTA Stock Forecast for 2026
Our AI model gives Pasithea Therapeutics (KTTA) a 6-month price target of $0.59 — 1.7% upside from the current price of $0.58 — implying a climb toward that level through the rest of 2026. The target updates daily as new KTTA financial, technical, and alternative-data signals come in.
KTTA Price Prediction for 2027–2030
AltIndex does not publish a multi-year model — alternative data is most predictive over the next 6–12 months. Extending the current trajectory as a simple linear extrapolation projects KTTA toward $0.65 by 2030, but long-range estimates carry far more uncertainty and should be treated as directional only. The more reliable signal is whether Pasithea Therapeutics’s AI Score and the drivers above keep improving over time.
Pasithea Therapeutics (KTTA) Monthly Price Forecast
| Month | Forecast | vs Current |
|---|---|---|
| Oct 2026 | $0.58 | +0.3% |
| Nov 2026 | $0.58 | +0.6% |
| Dec 2026 | $0.59 | +0.9% |
| Jan 2027 | $0.59 | +1.1% |
| Feb 2027 | $0.59 | +1.4% |
| Mar 2027 | $0.59 | +1.7% |
Straight-line projection from the latest price ($0.58) toward our 6-month AI target of $0.59. An estimate, not a month-by-month model.
See how AltIndex’s AI Score picks have performed →Similar companies
View All →
Frequently Asked Questions: Pasithea Therapeutics Price Prediction
On September 3, Pasithea Therapeutics (KTTA) was assigned a Hold with a target price of $0.59. This signal was predicated on several factors, including a long-term increase in Twitter followers.
The conviction in the pick is low due to the limited amount of alternative data available.
Based on Alternative Data, Pasithea Therapeutics is a hold.
Alternative data suggests that it's recommended to approach Pasithea Therapeutics (KTTA) with caution. While there are positive indicators, the overall assessment suggests a hold based on Alternative Data analysis. However, this information should not be considered financial advice.
With an AI score of 53, the KTTA stock forecast suggests stability.
To predict the price for KTTA in 2027, we can extrapolate the AI price target. This approach projects KTTA's price to reach $0.59.
To predict the price for KTTA in 2030, we can again extrapolate the AI price target. This approach projects KTTA's price to reach $0.65.
When predicting the price for KTTA, our approach incorporates multiple scores assessing different aspects of the company. The Brand score measures growth and engagement across social media channels, indicating audience reach. The Employee score evaluates workforce health, considering job postings, business outlook, and employee ratings. The Customer score examines engagement on websites, app downloads, and sentiment in stock forums. Lastly, the Fundamental score analyzes financial statements and analyst ratings. By evaluating this data, we gain a holistic view of the company's performance, enabling more informed price predictions.
Based on technical analysis of how the price has moved over the last 6 months is hard to tell since there has been no significant change in the price today to base a prediction on. Note that this is a simplistic analysis and should be used with caution, as prices are influenced by a myriad of factors.
Know the moment Pasithea Therapeutics’s price target changes
Get KTTA alerts
